Clinical and immunological worsening in a patient affected with Waldenstrom macroglobulinemia and anti-mag neuropathy after treatment with rituximab.
Gironi
Maira
M
Neurology Department, IRCCS Don C. Gnocchi Foundation, Milano, Italy. mgironi@dongnocchi.it
Saresella
M
M
Ceresa
L
L
Calvo
M
M
Ferrante
P
P
Merli
F
F
Nemni
R
R
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000097:blood; D015704:CD4 Antigens / Q000097:blood; D016827:CD8 Antigens / Q000097:blood; D018450:Disease Progression; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects; D018950:Lipopolysaccharide Receptors / Q000097:blood; D008875:Middle Aged; D009422:Nervous System Diseases / Q000150:complications / Q000276:immunology; D000069283:Rituximab; D008258:Waldenstrom Macroglobulinemia / Q000150:complications / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D015704:CD4 Antigens; D016827:CD8 Antigens; D007155:Immunologic Factors; D018950:Lipopolysaccharide Receptors; D000069283:Rituximab